[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-grade-intraepithelial-neoplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-grade-intraepithelial-neoplasia":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100651225","clinical-application-of-an-ai-based-dissection-trajectory-prediction-system-adtps-in-endoscopic-submucosal-dissection-100651225",false,"NCT07757906","Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection","Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection: A Prospective Paired Diagnostic Study and a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Chinese patients aged 18-80 years.\n\nLesions meeting ESD indications for esophageal, gastric, or colorectal early cancer or high-grade intraepithelial neoplasia, as defined by:\n\nNon-invasive tumors regardless of size; or\n\nDifferentiated-type intramucosal carcinoma without ulceration, regardless of size; or\n\nDifferentiated-type intramucosal carcinoma with ulceration and a diameter ≤3 cm; or\n\nUndifferentiated-type intramucosal carcinoma without ulceration and a diameter ≤2 cm.\n\nPlanned to undergo ESD treatment.\n\nNo prior treatment for the lesion (including ESD, surgery, radiotherapy, chemotherapy, etc.).\n\nPlatelet count \\>100 × 10⁹\u002FL and PT-INR \\\u003C1.5, with antiplatelet agents (aspirin, clopidogrel, etc.) discontinued for at least 5 days.\n\nAmerican Society of Anesthesiologists (ASA) physical status grade I or II.\n\nVoluntarily signed informed consent.\n\nExclusion Criteria:\n\n* Patients currently undergoing dialysis.\n\nPatients with severe cardiopulmonary disease or other severe comorbidities that may increase the risk of the ESD procedure.\n\nPregnant or breastfeeding women.","ALL","18 Years","80 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this prospective paired diagnostic study and single-center, randomized controlled trial, patients with early esophageal squamous neoplasia or high-grade intraepithelial neoplasia meeting the inclusion and exclusion criteria will be enrolled in a paired diagnostic cohort (60 patients) and subsequently randomly assigned (1:1) to receive endoscopic submucosal dissection (ESD) with AI-based Dissection Trajectory Prediction System (ADTPS) guidance or conventional ESD (without AI). Clinical data and operator workload scores (NASA-TLX) are collected during the procedure, and postoperative follow-up assessments are performed at days 1, 3, 7, and 14. The study aims to analyze the impact of ADTPS on the mean single-dissection time and operator workload in patients undergoing ESD by comparing the efficacy differences between the experimental and control groups. Additionally, the study investigates the effects of ADTPS on other postoperative complications including R0 resection rate, muscularis propria injury, intraoperative bleeding, perforation (acute and delayed), and total procedure time; conducts a comparative analysis of the safety and efficiency of AI-assisted versus conventional ESD; and develops effective clinical strategies for optimizing dissection trajectory and reducing complications in endoscopic submucosal dissection.",[27,28,29],"Esophageal Squamous Cell Carcinoma (ESCC)","High-Grade Intraepithelial Neoplasia","AI-Based Dissection Trajectory Prediction System",[31,32,33,34,35,36,37],"Artificial intelligence","R0 resection","Procedural efficiency","NASA-TLX","Randomized controlled trial","Dissection trajectory prediction","Endoscopic submucosal dissection","NOT_YET_RECRUITING","2026-08-06",{"date":41,"type":42},"2026-08-11","ACTUAL",{"date":44,"type":21},"2026-07-29",{"date":46,"type":21},"2027-10-01",{"name":48,"class":49},"Qilu Hospital of Shandong University","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":78,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100521874","phase-2-phase-ii-study-of-artesunate-ointment-for-the-treatment-of-vulvar-high-grade-squamous-intraepithelial-lesions-vulvar-hsil-vin23-100521874","NCT06075264","Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2\u002F3)","A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)","ART-VIN IIB","Inclusion Criteria:\n\n* Adult women age ≥ 18 years\n* Capable of informed consent\n* Able to collaborate with planned follow-up (transportation, compliance history, etc)\n* Biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2\u002F3, HSIL), including both new and recurrent disease. A biopsy diagnosis of vulvar high-grade squamous intraepithelial lesion within the previous 3 months which was not excised or otherwise treated may be accepted for study entry.\n* Positive HPV test at study entry (any genotype).\n* Women of childbearing potential agree to use birth control during the dosing phase (through week 8).\n* Laboratory values at Screening of:\n\n  * Serum alanine transaminase (SGPT\u002FALT) \\\u003C 5 x upper limit of normal (ULN)\n  * Serum aspartate transaminase (SGOT\u002FAST) \\\u003C 5 x ULN\n  * Serum Bilirubin (total) \\\u003C 2.5 x ULN\n  * Serum Creatinine ≤ 1.5 x ULN\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Concurrent anal, vulvar, or cervical cancer\n* HIV-positive participants with a CD4 count \\\u003C 200\n* Participants infected with HIV-1 if not on a stable, suppressive antiretroviral therapy (ART) regimen.\n* Unwillingness to undergo an excisional procedure at week 18 to either remove HSIL lesions, or to document histologic regression at a site where HSIL was present at study entry.\n* Currently receiving systemic chemotherapy or radiation therapy for another cancer.\n* Concomitant use of Efavirenz for HIV antiretroviral treatment\n* Concomitant use of strong UGT inhibitors\n* Concomitant use of imiquimod, cidofovir, or 5-fluorouracil (5-FU) for the duration of the study\n* Concurrent dermatological conditions affecting the vulva (e.g., herpetic lesion, Crohn's disease, hidradenitis suppurativa) or vulvar dermatoses (e.g., lichen sclerosis or planus, atopic dermatitis, genital atrophy).\n* Concurrent treatment with systemic corticosteroids","FEMALE",{"count":60,"type":21},27,[62],"PHASE2","This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2\u002F3).",[65,66,67,68,69,70,71,72,73,74,75,76,77],"Vulvar Diseases","HPV Infection","Vulvar HSIL","Pre-Cancerous Dysplasia","HPV Disease","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia",[79,80,81,82,83,84,85,86,87],"topical treatment","ointment","non-surgical","vulvar cancer prevention","high-risk HPV","human papillomavirus","HPV","vulvar HSIL","High grade lesions","RECRUITING","2025-08-13",{"date":91,"type":42},"2025-08-14",{"date":93,"type":42},"2023-12-06",{"date":95,"type":21},"2027-12",{"name":97,"class":98},"Frantz Viral Therapeutics, LLC","INDUSTRY",5,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100546016","comparison-of-pcle-and-eb-in-gastric-lesion-diagnosis-100546016","NCT06389448","Comparison of pCLE and EB in Gastric Lesion Diagnosis","Comparison of Probe-based Confocal Laser Endomicroscopy and Traditional Endoscopic Biopsies in the Diagnosis of Gastric Cancer and Precancerous Lesions: a Prospective Multicenter Comparative Study","Inclusion Criteria:\n\n* Over 18 years old and under 75 years old;\n* Patients with pathological diagnosis of LGIN, HGIN or early gastric cancer after conventional endoscopy biopsy, whose lesion has clear boundaries under endoscopic observation and is to be admitted for ESD surgery;\n* Patients who meet the indications for endoscopic resection of early gastric cancer, or LGIN patients who intend to undergo ESD surgery;\n* Patients who are able to provide pathological specimens\u002Fsections of previous endoscopic biopsy (in principle, it should be a case of this center).\n\nExclusion Criteria:\n\n* Patients with advanced gastric cancer or previous gastrectomy;\n* Patients with severe cardiopulmonary dysfunction, liver cirrhosis, renal dysfunction, acute gastrointestinal bleeding, esophageal-gastro varices, and coagulation disorders;\n* Patients who have a positive result in the fluorescein sodium allergy test;\n* Pregnant and lactating women;\n* Patients who have psychiatric disorders and are unable to cooperate with endoscopy or sign informed consent.","75 Years",{"count":109,"type":21},366,[24],"This is a prospective multicenter comparative study, aiming to compare probe-based confocal laser endomicroscopy (pCLE) and endoscopic biopsies in the diagnosis of the whole specific gastric lesion especially for distinguishing low grade intraepithelial neoplasia (LGIN) from high grade intraepithelial neoplasia (HGIN) and create an endoscopic image database for the follow-up research.",[113,77,114,115],"Low Grade Intraepithelial Neoplasia","Early Gastric Cancer","Gastric Intraepithelial Neoplasia",[117,118,119,120],"confocal laser endomicroscopy","endoscopic biopsy","Intraepithelial Neoplasia","gastric cancer","2024-05-06",{"date":123,"type":42},"2024-05-07",{"date":125,"type":42},"2024-04-11",{"date":127,"type":21},"2026-10",{"name":129,"class":49},"Huazhong University of Science and Technology",1]